Rhodes Jason P, DIR, reported an open-market or private sale at Dyne Therapeutics, Inc. involving 63643.000000 shares for an estimated $1667446.60. Reported holdings after the transaction were 751411.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
No officer title
Shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 13, 2026.
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.8788 to $26.48 inclusive. The Reporting Persons undertake to…
The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture As…
The shares are owned directly by Atlas Venture Opportunity Fund II, L.P. ("AVOF II"). Atlas Venture Associates Opportunity II, LP ("AVAO II LP") is the general partner of AVOF II. Atlas Venture Associ…
The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). The general partner of AVOF I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates…
The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $25.00 to $25.8916 inclusive.
The shares are held directly by AVA XI LP. AVA XI LLC is the general partner of AVA XI LP. The Reporting Person is a member of AVA XI LLC and disclaims Section 16 beneficial ownership of the securitie…
0 other filings
0 recent txs